Objective To explore the mechanism of malt alcohol extract improving depression-like behavior induced by CUMS in rats by regulating gut microbiota.Methods The depression model of rats was established using an 8-weeks CUMS procedure,and the administration group was given low(59.6 mg·kg-1)and high(178.8 mg·kg-1)doses of malt alcohol extract,respectively.The depression-like behavior of rats was evaluated by classic behavioral test.The composition of intestinal microbiota of rats was analyzed by 16S rRNA sequencing.The morphological changes of colon were observed by hematoxylin and eosin(HE),the expression of ZO-1 and Occludin in colon was detected by immunofluorescence(IF),and the expression of IL-10,IL-1βand 5-HT were detected by ELISA.Results The low dose of malt alcohol extract attenuated the depressive behavior and restored the expression of 5-HT in the brain of CUMS rats.16S rRNA sequencing results showed that the diversity and relative abundance of gut microbiota changed after treatment with the low dose of malt alcohol extract.ELISA results showed that the low dose of malt alcohol extract significantly reversed the CUMS-induced reduction of IL-10 and elevation of IL-1 β.HE results showed that the low dose of malt alcohol extract significantly ameliorated CUMS-induced structural damage in colon.IF results showed increased protain expression of intestinal epithelial barrier tight junction proteins ZO-1 and Occludin by the low dose of malt alcohol extract.Conclusion The low dose of malt alcohol extract can ameliorate CUMS-induced depressive-like behavior in rats by modulating intestinal flora,restoring 5-HT expression in the brain,inhibiting inflammation,and repairing the intestinal barrier.

Berberine,an isoquinoline alkaloid,is abundant in plants such as Coptis and Phellodendri.It exhibits a wide range of pharmacological activities and has been effectively applied in the clinical treatment of metabolic diseases,infectious diseases,and inflammation.In recent years,berberine's anti-tumor effects have garnered significant attention.Research has demonstrated that berberine can inhibit tumor progression via multiple pathways,including inducing tumor cell apoptosis,regulating the tumor microbiome,arresting the cell cycle,inhibiting tumor angiogenesis,and enhancing the efficacy of tumor immunotherapy.Additionally,berberine can synergistically increase the sensitivity of chemotherapeutic drugs and reduce drug resistance by modulating key signaling pathways such as PI3K/Akt,MAPK,and NF-κB.The antioxidant and immunomodulatory properties of berberine further expand its potential for anti-tumor applications.Based on the findings from basic and clinical research,this review systematically summarizes the latest advances in berberine's anti-tumor mechanisms and clinical applications.It also discusses the challenges and potential solutions in the clinical translation of berberine for cancer therapy,providing a theoretical basis for its development as a novel anti-tumor drug.

Objective To summarize the role of clinical pharmacists in pharmaceutical care in the treatment of patients with pneumocystis jirovecii pneumonia secondary to immune-mediated colitis.Methods The association of immune-mediated colitis induced by serplulimab was evaluated by clinical pharmacist,anti-infective regimen for pneumocystis jirovecii pneumonia was put forward,addressed concerns regarding the impact of trimethoprim/sulfamethoxazole on the efficacy of fecal microbiota transplantation,pharmaceutical care for whole therapeutic process of the patient was monitored.Results Through pharmaceutical care and collaborating with physicians,the patient's pneumocystis jirovecii pneumonia was significantly improved,and the clinical and endoscopic remission of immune-mediated colitis after two fecal microbiota transplantation were achieved.Conclusion To ensure the safety and effectiveness of immune-mediated colitis and pneumocystis jirovecii pneumonia for patients,clinical pharmacists should play the role of participation and pharmaceutical care.

Objective To investigate the key factors influencing the willingness of chronic disease patients to participate in home pharmaceutical services.Methods The study adopted the data from inner Mongolia and northeast China set of the drug aging system research for China.The Null Importance method was employed to identify key factors influencing the willingness of chronic disease patients to participate in home pharmaceutical services.The logistic regression model was constructed and evaluated the impact of feature selection through 5 fold cross-validation and accuracy and AUC values.Results 10 key factors were selected by the Null Importance method and the performance of the logistic regression model was improved after feature selection.The factors which significantly affected patients' willingness to accept home pharmaceutical services included the number of accessible information sources(OR=1.261,95％CI=1.182～1.345),medication therapeutic indication cognition(OR=1.342,95％CI=1.124～1.603),the presence the drug packaging or not(OR=1.218,95％CI=1.015～1.462),medication adherence(OR=0.881,95％CI=0.839～0.925),medication literacy(OR=0.631,95％CI=0.488～0.817),the degree of know of medication guidance services(OR=1.211,95％CI=1.017～1.442).Conclusion The logistic model refined by the Null Importance feature selection method demonstrated good performance and was conducive to analyzing the factors influencing the willingness of chronic disease patients to participate in home pharmaceutical care.

Objective To understand the current situation of the management of patients'self-provided infusion drugs in secondary and above general hospitals in China,and to provide a theoretical and practical basis for improving the management system.Methods The annual pharmacy professional quality control work survey conducted by the National Pharmaceutical Management Professional Quality Control Center was used to obtain information on the management of patients'self-provided infusion drugs in secondary and above general hospitals in 31 provinces(autonomous regions and municipalities directly under the central government)and the Xinjiang Production and Construction Corps of Chinese mainland from 2020 to 2022,and was summarized and calculated using data-processing software.Results The total number of secondary and above general hospitals included in the analysis from 2020 to 2022 is 4 786,5 063 and 6 041,respectively.In 2022,compared with 2020,the percentage of hospitals allowing patients to use self-provided infused drugs decreased from 55.08％to 48.54％,the percentage of hospitals that have established a system for managing patients' self-provided drugs increased from 81.54％to 98.09％,and the percentage of hospitalized patients' use of self-provided drugs that are all documented in their medical orders increased from 79.76％to 90.72％.The types of drugs that hospitals allow patients to use for self-provided infusion are mainly antitumor drugs,the places where self-provided infusion drugs are dispensed are mainly clinical departments(wards),and the main source of self-provided infusion drugs is self-pickup by patients.Conclusion Hospitals should establish a management system for patients'self-provided drugs,strengthen the information management of self-provided infusion drugs,and ensure drug supply and medication safety for patients.

Objective Based on the SWOT analysis method,the temporary medical order dispensing service model of pharmacy intravenous admixture service(PIVAS)of M Hospital was constructed and its implementation effect was evaluated,so as to provide reference for other medical institutions to carry out PIVAS temporary dispensing services.Methods SWOT analysis was used to analyze the advantages,disadvantages,opportunities and threats of PIVAS in M Hospital,and targeted operation strategies and practices were proposed.The safety of intravenous medication,the level of pharmacy service and the cost-effectiveness of the department were used to evaluate the implementation effect of PIVAS temporary medical order dispensing service.Results After the operation strategy of PIVAS temporary medical order dispensing service was constructed and implemented based on SWOT analysis,the time of a single medical order for PIVAS labeling in M Hospital was significantly decreased from(7.19±0.06)s/bag to(6.06±0.09)s/bag(P＜0.05);and the number of errors was significantly reduced from(32.50±2.54)pieces/quarter to(19.75±0.59)pieces/quarter(P＜0.05);The qualified rate of temporary prescription increased from(60.52±1.17)％to(90.63±1.72)％(P＜0.05);The qualified rate of finished infusion delivery time increased from(80.63±1.66)％to(90.80±2.98)％(P＜0.05);The satisfaction rate of PIVAS service in the ward increased from 50％to 90％(P＜0.05);the cost of blending decreased from(3.50±0.05)yuan/bag to(3.00±0.12)yuan/bag(P＜0.05).Conclusion The operation strategy of PIVAS temporary medical order dispensing service of M Hospital based on SWOT analysis gives full play to its own advantages,provides more comprehensive and high-quality services for clinicians and patients,ensures the safety and timeliness of patients' medication,and improves the economic efficiency of the department,which is worthy of reference and promotion.

Human cytomegalovirus(HCMV)infection can manifest as asymptomatic,systemic symptoms or tissue invasive disease,etc.After infection,it can establish a persistent or latent infection in the host,and viral reactivation occurs in the case of immunocompromised organisms and leads to serious diseases.With the widespread use of antiviral drugs,the prognosis of HCMV infection has been improved,but long-term antiviral therapy is accompanied by the emergence of adverse drug reactions or drug resistance,and refractory or drug-resistant HCMV infections have become a clinical problem which should not be ignored and solved urgently.Therefore,this article reviews the latest advances of treatment strategies for HCMV infection for clinical reference.

Objective To further standardize the rational use of anti-IgE monoclonal antibody treatment for allergic asthma.Methods Related issues in anti-IgE monoclonal antibody treatment management were identified through systematic reviews and clinical experience.A quality assessment was conducted using evidence grading system,and the Delphi method was employed to establish consensus recommendations,developed expert consensus on physician-pharmacist collaborative management of anti-IgE monoclonal antibody treatment for allergic asthma(referred to as the Consensus).Results The consensus,represented by the omalizumab,formulated 12 recommendations,encompassing the work model of physician-pharmacist collaborative management,clinical pathways,hierarchical diagnosis and treatment systems,and training and assessment.It provided a standardized management framework for physician-pharmaceutical collaborative management of omalizumab treatment in allergic asthma.Conclusion This consensus provides practical recommendations for pharmacists to engage in omalizumab treatment management,aiming to improve patients'medication compliance and disease prognosis,and optimize the clinical value of anti-IgE monoclonal antibody.

According to the latest 2022 Global Cancer Burden report released by the World Health Organization's International Agency for Research on Cancer,the number of newly diagnosed cancer patients worldwide continues to rise,and this trend is expected to become more pronounced by 2050.In the same year,China's cancer incidence report for 2022 revealed that both the number of new cancer cases and cancer-related deaths have continued to increase compared to previous years,indicating a worrying situation.Amid the growing demand for effective cancer therapies,the development of anti-cancer drugs is gaining significant momentum.Traditional Chinese Medicine(TCM)has begun to play an increasingly prominent role in the anti-cancer drug market,contributing a unique"Chinese solution"to global cancer treatment.However,TCM is characterized by its multi-component,multi-pathway,and multi-target nature,making it challenging to comprehensively study its anti-cancer mechanisms using traditional research models.Consequently,there is an urgent need to develop new research models that align with the characteristics of TCM.Organoids,as an emerging technology and an ideal preclinical model for human diseases,address the limitations of traditional disease models in TCM research.Their application in the study of TCM's anti-cancer effects is rapidly expanding.This article reviews and summarizes the use of organoid technology in TCM-based anti-cancer research,analyzing its advantages,limitations and developmental trends.

Objective To investigate the effects of Jinfukang on the growth of human lung cancer H358 cell xenografts in nude mice and its regulatory role in the TRIM52-mediated Wnt/β-catenin signaling pathway.Methods Human lung cancer H358 cells were cultured,and a subcutaneous xenograft model was established in nude mice.The mice were randomly divided into four groups:0.9％sodium chloride solution,cisplatin(3 mg·kg-1,intraperitoneal injection every 3 days),Jinfukang(0.4 mL,daily oral administration),and Jinfukang combined with cisplatin.Each group included 6 mice.After 15 days of continuous treatment,the tumor growth inhibition rate was calculated.Hematoxylin and eosin(H&E)staining was performed to observe tumor histopathological changes.TUNEL assay was used to evaluate apoptosis and calculate the apoptotic index.The relative mRNA expression levels and protein expression of TRIM52,PCNA,c-Myc,β-catenin,and Cyclin D1 were assessed by Real-time PCR and western blot,respectively.Results Compared with the saline group,Jinfukang,cisplatin,and Jinfukang combined with cisplatin treatments significantly inhibited tumor growth(P＜0.05).The combination group exhibited the most pronounced anti-tumor effect,slightly better than cisplatin alone,although the difference was not statistically significant(P＞0.05).Histopathological analysis and apoptosis indices revealed that the combination group showed the most severe necrosis and the highest level of apoptosis compared to other groups(P＜0.05).Furthermore,the combination group significantly downregulated the mRNA(P＜0.05)and protein(P＜0.05)expression levels of Cyclin D1,PCNA,TRIM52,β-catenin and c-Myc.Conclusion Jinfukang effectively inhibits the growth of human lung cancer H358 xenografts,disrupts tumor cell structure,and promotes apoptosis.Its anti-tumor effect is further enhanced when combined with cisplatin.The underlying mechanism may involve the downregulation of TRIM52 expression,leading to the suppression of Wnt/β-catenin signaling pathway activity and augmentation of anti-tumor efficacy.